Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 1997

View Archived Issues

Bristol-Myers Squibb acquires broad-spectrum antitumor agents

FDA releases Staar's implantable contact lens for phase II trials

Complete genomic sequence of H. pylori revealed

Etidronate reduces fractures in corticosteroid-induced osteoporosis

Beta Peptide Foundation launches product line which fights cell aging process

Cephalon reports cysteine/serine protease inhibitors with broad therapeutic potential

Oral carbapenem antibacterial agents from Lederle (Japan)

Orally active PDE IV inhibitors from Merck Frosst

TNP-470 for treatment of mesangial proliferative glomerulonephritis

Oncormed allowed U.S. patent for BRCA1 gene

First European clinical trials of pranlukast reported

Lilly reports new agent for brain injury

Guilford receives government contract for cocaine addiction research

Diversa enters into collaboration for the development of novel enzymatic process

Mathematical model for predicting S-15535 metabolism in humans

Regeneron issued U.S. patent for angiogenesis antagonist

Almotriptan metabolic pathway in humans described

Galanin receptor research collaboration between Synaptic and Warner-Lambert

Shire to merge with Richwood

FDA lifts injunction on Sonus' EchoGen Emulsion

Analysis of Macritonin phase II/III trial complete; Cortecs to seek European approval

FDA approves extended shelf life for Integra artificial skin

Open-label trial of Glaxo Wellcome anti-HIV drug begins

Oral bioavailability of palinavir studied in various animal models

Metabolic studies on sameridine described at ISSX meeting

Metabolism of antidepressant studied in vivo

Granocyte approved for marketing in 14 additional countries

Structural Bioinformatics and BioChem Therapeutic sign collaborative agreement

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...